# Elevance Renewable Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elevance-renewable-sciences

- Industry: Chemicals
- Headquarters: Woodridge, US
- Website: www.elevance.com
- Total disclosed funding: $232M
- Latest round: Series D (Jun 24, 2011)
- Investors on record: 4

## About

Elevance Renewable Sciences, Inc. focuses on developing and commercializing renewable chemical technologies to transform natural oils into high-performance products across various industries.Founded in 2007, Elevance Renewable Sciences, Inc. operates from Woodridge, US, and specializes in converting renewable resources into specialty chemicals. The company has made significant strides in its business operations without any reported pivots or changes. K'lynne Johnson serves as the CEO. As of June 2018, Elevance raised USD 18 mn in venture funding, marking a pivotal moment in its growth trajectory, with a total amount raised of USD 18 mn and twelve completed deals to date.Elevance specializes in providing innovative renewable chemical solutions that convert natural oils into high-performance products. Their offerings cater to various industries, including personal care, automotive, and coatings, emphasizing eco-friendly and sustainable alternatives. The company's expertise lies in leveraging advanced technology to create unique formulations that meet the diverse needs of its clients, ranging from small businesses to large corporations across multiple global markets.In the fiscal year 2010, Elevance Renewable Sciences, Inc. reported a revenue of USD 21,188,000 with an EBITDA of USD -15,068,000, reflecting the company's active engagement in the renewable chemicals sector.Elevance Renewable Sciences, Inc. is planning to launch new product lines that enhance its renewable chemical offerings. The company aims to expand its market reach into Europe and parts of Asia by 2025. The funds raised in June 2018, amounting to USD 18 mn, will support these initiatives, facilitating product development and market entry strategies.

## Funding rounds

- Series D, Jun 24, 2011, $50M — TPG, Naxos Capital Partners (Luxembourg)
- Series C, Dec 6, 2010, $104M — TPG, TPG Biotech, TotalEnergies, Naxos Capital Partners (Luxembourg)
- Series B, May 28, 2008, $34M — TPG, TPG Biotech
- Series B, Nov 30, 2007, $45M — TPG, TPG Biotech

## Investors

- TPG (https://capitalatlas.ai/funds/tpg) — Series B, Series C, Series D
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series B, Series C
- TotalEnergies — Series C
- Naxos Capital Partners (Luxembourg) (https://capitalatlas.ai/funds/naxos-capital-partners-luxembourg) — Series C, Series D